Hanx Biopharmaceuticals Completes HKD 0.59 Million Share Buyback, Lifting Treasury Shares to 220,900

Bulletin Express04-16 20:03

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market repurchase of 20,100 H shares on 16 April 2026, paying a total of HKD 0.59 million at prices ranging from HKD 28.48 to HKD 30.00 per share. The volume-weighted average repurchase price stood at HKD 29.39.

Following the transaction: • Issued shares outstanding (excluding treasury shares) decreased to 135.998 million, down 0.015 % from 136.018 million on 15 April 2026. • Treasury shares rose to 220,900, representing 0.16 % of the company’s issued shares at the repurchase-mandate approval date (12 February 2026). • Total issued share capital remained unchanged at 136.219 million shares, as the repurchased stock is being held in treasury rather than cancelled.

Under the existing mandate, the company is authorised to buy back up to 13.622 million shares. Cumulative repurchases under this mandate now total 220,900 shares, equivalent to 0.16 % of the authorised limit.

In accordance with Hong Kong Listing Rules, Hanx Biopharmaceuticals is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, expiring on 16 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111330059?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111330059","market":"us","top_or_hot":-1,"title":"Hanx Biopharmaceuticals Completes HKD 0.59 Million Share Buyback, Lifting Treasury Shares to 220,900","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market repurchase of 20,100 H shares on 16 April 2026, paying a total of HKD 0.59 million at prices ranging from HKD 28.48 to HKD 30.00 per share. The volume-weighted average repurchase price stood at HKD 29.39.</p>\n<p>Following the transaction:\n• Issued shares outstanding (excluding treasury shares) decreased to 135.998 million, down 0.015 % from 136.018 million on 15 April 2026.  \n• Treasury shares rose to 220,900, representing 0.16 % of the company’s issued shares at the repurchase-mandate approval date (12 February 2026).  \n• Total issued share capital remained unchanged at 136.219 million shares, as the repurchased stock is being held in treasury rather than cancelled.</p>\n<p>Under the existing mandate, the company is authorised to buy back up to 13.622 million shares. Cumulative repurchases under this mandate now total 220,900 shares, equivalent to 0.16 % of the authorised limit.</p>\n<p>In accordance with Hong Kong Listing Rules, Hanx Biopharmaceuticals is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, expiring on 16 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharmaceuticals Completes HKD 0.59 Million Share Buyback, Lifting Treasury Shares to 220,900</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharmaceuticals Completes HKD 0.59 Million Share Buyback, Lifting Treasury Shares to 220,900\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-16 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market repurchase of 20,100 H shares on 16 April 2026, paying a total of HKD 0.59 million at prices ranging from HKD 28.48 to HKD 30.00 per share. The volume-weighted average repurchase price stood at HKD 29.39.</p>\n<p>Following the transaction:\n• Issued shares outstanding (excluding treasury shares) decreased to 135.998 million, down 0.015 % from 136.018 million on 15 April 2026.  \n• Treasury shares rose to 220,900, representing 0.16 % of the company’s issued shares at the repurchase-mandate approval date (12 February 2026).  \n• Total issued share capital remained unchanged at 136.219 million shares, as the repurchased stock is being held in treasury rather than cancelled.</p>\n<p>Under the existing mandate, the company is authorised to buy back up to 13.622 million shares. Cumulative repurchases under this mandate now total 220,900 shares, equivalent to 0.16 % of the authorised limit.</p>\n<p>In accordance with Hong Kong Listing Rules, Hanx Biopharmaceuticals is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, expiring on 16 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1111330059","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111330059","pubTimestamp":1776341002,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market repurchase of 20,100 H shares on 16 April 2026, paying a total of HKD 0.59 million at prices ranging from HKD 28.48 to HKD 30.00 per...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉克斯生物制药完成59万港元股份回购，库存股增至22.09万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market repurchase of 20,100 H shares on 16 April 2026, paying a total of HKD 0.59 million at prices ranging from HKD 28.48 to HKD 30.00 per share. The volume-weighted average repurchase price stood at HKD 29.39.\nFollowing the transaction:\n• Issued shares outstanding (excluding treasury shares) decreased to 135.998 million, down 0.015 % from 136.018 million on 15 April 2026.  \n• Treasury shares rose to 220,900, representing 0.16 % of the company’s issued shares at the repurchase-mandate approval date (12 February 2026).  \n• Total issued share capital remained unchanged at 136.219 million shares, as the repurchased stock is being held in treasury rather than cancelled.\nUnder the existing mandate, the company is authorised to buy back up to 13.622 million shares. Cumulative repurchases under this mandate now total 220,900 shares, equivalent to 0.16 % of the authorised limit.\nIn accordance with Hong Kong Listing Rules, Hanx Biopharmaceuticals is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, expiring on 16 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111330059","isCrawlerRequest":true}